These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1919423)

  • 1. Cost-benefit analysis of non-pharmacological treatment of hypertension.
    Johannesson M; Aberg H; Agréus L; Borgquist L; Jönsson B
    J Intern Med; 1991 Oct; 230(4):307-12. PubMed ID: 1919423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of a cardiovascular multiple-risk-factor intervention programme in treated hypertensive men.
    Johannesson M; Agewall S; Hartford M; Hedner T; Fagerberg B
    J Intern Med; 1995 Jan; 237(1):19-26. PubMed ID: 7830026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicomponent intervention versus usual care for management of hypertension in rural Bangladesh, Pakistan and Sri Lanka: study protocol for a cluster randomized controlled trial.
    Jafar TH; Jehan I; de Silva HA; Naheed A; Gandhi M; Assam P; Finkelstein EA; Quigley HL; Bilger M; Khan AH; Clemens JD; Ebrahim S; Turner EL; ; Kasturiratne A
    Trials; 2017 Jun; 18(1):272. PubMed ID: 28606184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacy-based health promotion programme in hypertension: cost-benefit analysis.
    Côté I; Grégoire JP; Moisan J; Chabot I; Lacroix G
    Pharmacoeconomics; 2003; 21(6):415-28. PubMed ID: 12678568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More bang for the buck in managing high blood pressure.
    Smith MD; McGhan W
    Bus Health; 1996 May; 14(5):44-7. PubMed ID: 10157918
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
    Yokoyama K; Yang W; Preblick R; Frech-Tamas F
    J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
    Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
    Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The costs of treating hypertension in Sweden. An empirical investigation in primary health care.
    Johannesson M; Borgquist L; Jönsson B
    Scand J Prim Health Care; 1991 Sep; 9(3):155-60. PubMed ID: 1754746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
    Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
    J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial.
    van der Laan DM; Elders PJ; Boons CC; Bosmans JE; Nijpels G; Hugtenburg JG
    Trials; 2017 Jan; 18(1):29. PubMed ID: 28103948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: a randomized controlled trial.
    Staessen JA; Den Hond E; Celis H; Fagard R; Keary L; Vandenhoven G; O'Brien ET;
    JAMA; 2004 Feb; 291(8):955-64. PubMed ID: 14982911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of hypertension treatment.
    Odell TW; Gregory MC
    J Gen Intern Med; 1995 Dec; 10(12):686-8. PubMed ID: 8770721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the patient group for cost-effective withdrawal of antihypertensive therapy.
    Krakoff LR; Wassertheil-Smoller S
    Pharmacoeconomics; 1995 Mar; 7(3):221-8. PubMed ID: 10155311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving cost-effectiveness of hypertension management at a community health centre.
    Edwards PR; Lunt DW; Fehrsen GS; Lombard CJ; Steyn K
    S Afr Med J; 1998 May; 88(5):549-54. PubMed ID: 9638122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost estimation of hypertension management based on home blood pressure monitoring alone or combined office and ambulatory blood pressure measurements.
    Boubouchairopoulou N; Karpettas N; Athanasakis K; Kollias A; Protogerou AD; Achimastos A; Stergiou GS
    J Am Soc Hypertens; 2014 Oct; 8(10):732-8. PubMed ID: 25418495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators.
    Staessen JA; Byttebier G; Buntinx F; Celis H; O'Brien ET; Fagard R
    JAMA; 1997 Oct; 278(13):1065-72. PubMed ID: 9315764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of pharmacologic costs in the treatment of arterial hypertension. Approximation to a cost-effectiveness study].
    Alonso Moreno FJ; García Palencia M; Laborda Peralta M; Hermoso López A; Lopez de Castro F
    Aten Primaria; 1998 May; 21(9):607-12. PubMed ID: 9677744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Willingness to pay and willingness to accept in a patient-centered blood pressure control study.
    Gleason-Comstock J; Streater A; Goodman A; Janisse J; Brody A; Mango L; Dawood R; Levy P
    BMC Health Serv Res; 2017 Aug; 17(1):538. PubMed ID: 28784120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IX-1993 guidelines for management of mild hypertension. WHO/ISH Mild Hypertension Liaison Committee.
    Clin Exp Hypertens; 1993 Nov; 15(6):1363-95. PubMed ID: 8268896
    [No Abstract]   [Full Text] [Related]  

  • 20. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.